SymBio Pharmaceuticals Ltd represents values of innovation, collaboration, and patient-centric approach. With a strong corporate philosophy, the company focuses on developing novel therapies to address unmet medical needs. SymBio Pharmaceuticals Ltd believes in fostering strategic partnerships and actively engaging with key stakeholders to drive advancements in healthcare. Their commitment to scientific excellence and dedication to improving patients' lives fuel their mission to develop transformative treatments. As a forward-thinking pharmaceutical company, SymBio Pharmaceuticals Ltd prioritizes the health and well-being of individuals, guided by their core values and corporate philosophy.

SymBio Pharmaceuticals Ltd is primarily present in Japan. As a pharmaceutical company, SymBio focuses on developing and commercializing therapeutics for oncology and autoimmune diseases. Headquartered in Tokyo, Japan, the company has established a strong presence within its domestic market. SymBio Pharmaceuticals Ltd's innovative research and development efforts have led to the introduction of several important drugs in Japan. With a commitment to improving patient care and addressing unmet medical needs, SymBio Pharmaceuticals Ltd continues to expand its reach within the Japanese pharmaceutical industry.

SymBio Pharmaceuticals Ltd has achieved several significant milestones. In recent years, the company received approval for Treakisym, its flagship product which is used in the treatment of non-Hodgkin's lymphoma and other malignant lymphomas. SymBio Pharmaceuticals also successfully entered into licensing and collaboration agreements with renowned companies, expanding its global presence and creating opportunities for further growth. Moreover, the company received device approval for Cutisum, a new formulation of Treakisym, providing patients with an improved treatment option. These milestones demonstrate SymBio Pharmaceuticals' commitment to innovation and its dedication to advancing healthcare solutions for patients worldwide.

SymBio Pharmaceuticals Ltd was established in 2005 and is a biopharmaceutical company based in Japan. The company focuses on the development and commercialization of novel oncology therapeutics. With a strong commitment to research and development, SymBio Pharmaceuticals has successfully launched several products in the oncology field, including bendamustine hydrochloride, which is used in the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. SymBio Pharmaceuticals leverages its deep expertise in drug development and collaborations with global pharmaceutical companies to advance its pipeline of innovative therapies. The company is dedicated to making a meaningful impact in the healthcare industry by providing effective and safe treatment options for cancer patients.

The main competitors of SymBio Pharmaceuticals Ltd in the market are XYZ Pharmaceuticals and ABC Biotech.

SymBio Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

The business model of SymBio Pharmaceuticals Ltd is centered around the development and commercialization of innovative therapeutic drugs. Being a specialty pharmaceutical company, SymBio focuses on the research, clinical development, and distribution of pharmaceutical products, particularly in the field of oncology and autoimmune diseases. By leveraging its expertise in drug discovery and strategic partnerships, SymBio aims to bring novel and effective treatments to patients worldwide. With a commitment to addressing unmet medical needs, SymBio Pharmaceuticals Ltd strives to deliver high-quality and differentiated healthcare solutions to improve patients' lives.

De SymBio Pharmaceuticals K/W is 4,48.

De SymBio Pharmaceuticals KUV is 0,71.

De AlleAktien Kwaliteitsscore voor SymBio Pharmaceuticals is 3/10.

De verwachte SymBio Pharmaceuticals omzet is 12,93 mld. JPY.

De verwachte SymBio Pharmaceuticals winst is 2,05 mld. JPY.

SymBio Pharmaceuticals Ltd is a leading, globally active company that focuses on the development, approval, and marketing of innovative pharmaceuticals. The company was founded in Japan in 2005 and now has numerous branches worldwide. The company's business strategy is aimed at providing patients worldwide with access to high-quality therapy options that improve medical practice and enhance patients' quality of life. The company relies on targeted research and development as well as close collaboration with academic institutions, other pharmaceutical companies, and patient groups. SymBio Pharmaceuticals operates in three business areas: Pharma Products, Licensing & Development, and Clinical Trials. Pharma Products: SymBio Pharmaceuticals currently offers four products, all of which are approved in Japan. The company has launched Nipent® (Pentostatin), a medication for the treatment of hairy cell leukemia. Ramucirumab (Cyramza®) and Ibritumomab (Zevalin®) are approved in Japan and used in the field of oncology. Treakisym® is a medication for non-Hodgkin lymphomas and is also marketed in Taiwan. The company is working on adding more products and indications to its portfolio. Licensing & Development: SymBio Pharmaceuticals has extensive experience in licensing active substances and technologies from around the world, as well as in collaborating with partners in drug development. The company offers its customers a wide range of services, from early research to drug approval. Clinical Trials: SymBio Pharmaceuticals has conducted a wide range of clinical trials and has extensive expertise in the field of clinical studies, from Phase I to Phase III. The company works closely with academic institutions, other pharmaceutical companies, and CROs to conduct clinical trials. In recent years, SymBio Pharmaceuticals has pursued a successful growth strategy and expanded its business through strategic partnerships and acquisitions. For example, in 2018, the company acquired a majority stake in a company that produces and markets specialized oncology products. In the same year, SymBio announced plans to establish a new cancer research institute in collaboration with other research institutions. Overall, SymBio Pharmaceuticals believes in the importance of innovation and collaboration to meet the medical needs of patients worldwide. The company remains actively seeking new partnerships and acquisition opportunities to continuously expand its product line and services.

SymBio Pharmaceuticals keert een dividend van 0 JPY uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor SymBio Pharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van SymBio Pharmaceuticals is JP3383050006.

Het WKN van SymBio Pharmaceuticals is A1JMJE.

De ticker van SymBio Pharmaceuticals is 4582.T.

Binnen de laatste 12 maanden betaalde SymBio Pharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal SymBio Pharmaceuticals naar verwachting een dividend van 0 JPY betalen.

De dividendrendement van SymBio Pharmaceuticals is momenteel .

SymBio Pharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

SymBio Pharmaceuticals betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 JPY verwacht. Dit komt overeen met een dividendrendement van 0 %.

SymBio Pharmaceuticals wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van SymBio Pharmaceuticals van 7-11-2024 ter hoogte van 0 JPY te ontvangen, moest je het aandeel voor de ex-datum op 7-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 7-11-2024.

In het jaar 2023 heeft SymBio Pharmaceuticals 0 JPY aan dividenden uitgekeerd.

De dividenden van SymBio Pharmaceuticals worden in JPY uitgekeerd.